SCHEMBL3471002

SCHEMBL3471002

O=[C]c1cc(O)cc(OC=O)c1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL524065 0.81 LCK (0.43)
Methane SCHEMBL27792691 0.79 LCK (0.42)
SCHEMBL3471004 0.74 ALDH5A1 (0.39)
SCHEMBL3019632 0.73 BACE1 (0.50) EGFR
SCHEMBL19024853 0.73 BACE1 (0.41) EGFR
SCHEMBL24445876 0.72 CA12 (0.48)
SCHEMBL8804437 0.72 ALDH1A1 (0.48)
Resorcinol SCHEMBL28044421 0.72 CYP3A4 (0.50)
Phenol SCHEMBL28239137 0.71 CA12 (0.44)
Catechol SCHEMBL28164265 0.71 TTR (0.41) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100323969-A1 Compounds Binding to P-Selectin ASTELLAS PHARMA EUROPE B.V. (NL) 2010-12-23 US disclosed
US-20090062186-A1 Compounds Binding To P-Selectin YAMANOUCHI ERUOPE B.V. (NL) 2009-03-05 US disclosed
EP-1527086-B1 COMPOUNDS BINDING TO P-SELECTIN ASTELLAS PHARMA EUROP B V (NL) 2008-01-09 EP disclosed
US-20060217294-A1 Compounds binding to p-selectin YAMANOUCHI EUROPE B.V. 2006-09-28 US disclosed
EP-1527086-A1 COMPOUNDS BINDING TO P-SELECTIN YAMANOUCHI EUROPE B.V. (NL) 2005-05-04 EP disclosed
WO-2004018502-A1 COMPOUNDS BINDING TO P-SELECTIN YAMANOUCHI EUROPE B.V. (NL) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062186-A1 Compounds Binding To P-Selectin SELP, SELPLG, SELL EGFR 3499/4885
US-20100323969-A1 Compounds Binding to P-Selectin SELP, SELPLG, SELL EGFR 3499/4885
US-20060217294-A1 Compounds binding to p-selectin SELP, SELPLG, SELL EGFR 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.